A new study by researchers at the University of British Columbia, Vancouver has found patients with age-related macular degeneration (AMD) who received seven or more eye injections of the drug bevacizumab annually had a higher risk of having glaucoma surgery.
For their study, researchers reportedly looked at patients who had received intravitreous bevacizumab injections for exudative AMD, and cases were identified using glaucoma surgical codes for various procedures. For each case, reportedly 10 controls were identified, and the number of intravitreous bevacizumab injections received per year was determined for both cases and controls.
According to researchers, 74 cases of glaucoma surgery and 740 controls were identified. They found seven or more injections were associated with a significantly higher risk of glaucoma surgery.
The study was recently published online by JAMA Ophthalmology.
Click here to read the full press release.
Like what you read? Follow OphthalmologyWeb to keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.
Source: JAMA Ophthalmology